Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

The phase 2 GRIFFIN study of daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) for transplant-eligible, newly diagnosed multiple myeloma included a safety run-in phase followed by a randomized phase. The ongoing randomized phase has met its prespecified primary end point of an improved...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood Adv
Glavni autori: Voorhees, Peter M., Rodriguez, Cesar, Reeves, Brandi, Nathwani, Nitya, Costa, Luciano J., Lutska, Yana, Bobba, Padma, Hoehn, Daniela, Pei, Huiling, Ukropec, Jon, Qi, Ming, Lin, Thomas S., Richardson, Paul G.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2021
Teme:
Stimulus Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7903234/
https://ncbi.nlm.nih.gov/pubmed/33606004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003642
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items